Lupus Foundation of America supported study finds combination therapy that includes hydroxychloroquine may be beneficial to pregnant patients with lupus and/or antiphospholipid syndrome
What a way to kick off 2014! On Monday, January 13 2014 the House and Senate appropriators unveiled the Omnibus Appropriations bill. All 12 outstanding appropriations bills are rolled into one, including the all-important Labor-HHS-Education bill that houses many of our lupus programs. Thanks to the ongoing advocacy work by the Lupus Foundation of America and our network of activists and supporters, the news for lupus could not be better.
Children with lupus may have a higher risk for developing cancer – especially blood cancers such as non-Hodgkin’s lymphoma and leukemia – compared to children without lupus.
Take a look at some of our NEW and EXCITING auction items!
In her Expert Column, Dr. Joan T. Merrill, Medical Director, explains why antimalarial medicines are now used to treat lupus.
A new study that analyzed lupus treatment data from past global clinical trials suggests that when testing new drugs in combination with other background therapies, clinical trials should be designed to account for the effects that initial disease activity and background drug treatment have been shown to have on planned endpoints, like response and flare rates.
The outlook for positive pregnancy outcomes for women with lupus remains bright, but data obtained from a large insurance claims database highlights the need for specific education and counseling to pregnant women with lupus as well as close collaboration between the rheumatologist and the obstetrician throughout the pregnancy.
Although the overall risk is small, children born to mothers with lupus may have a higher risk of autism spectrum disorders than children born to mothers without the disease, according to the results of a study presented this week at the American College of Rheumatology Annual Scientific Meeting in San Diego.